Meta Description: LivaNova PLC shares rose over 2% on NASDAQ amid steady trading volumes and strong device market positioning. Key details for investors below.
Company Overview
LivaNova PLC is a global medical device company headquartered in London, United Kingdom. Founded in 1987, it has established a significant presence in therapeutic solutions across multiple segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support.
The Cardiopulmonary segment creates and markets heart-lung machines, oxygenators, and related surgical equipment. The Neuromodulation segment develops the VNS Therapy System for drug-resistant epilepsy, depression, and sleep apnea, and is advancing the VITARIA System for heart failure treatment. The Advanced Circulatory Support segment focuses on temporary life support products, including cardiopulmonary and respiratory solutions.
LivaNova serves hospitals, healthcare providers, neurosurgeons, perfusionists, and other medical professionals worldwide. The company collaborates with Verily to capture clinical biomarkers of depression, showing an interest in digital health integration.
Stock Performance
On the latest trading day, LivaNova PLC (NASDAQ: LIVN) closed at USD 53.37, reflecting a gain of USD 1.22 or +2.34%. This uptick signals market interest and follows a range movement between USD 32.48 and USD 58.91 over the past year.
Trading volume reached 243,067 shares, which is below the average daily volume of 662,609 shares. Lower volume days can indicate measured investor activity. The absence of dividends (last dividend: 0) suggests the company prioritizes reinvestment into growth and innovation rather than cash distributions to shareholders.
Market capitalization stands at approximately USD 2.91 billion, indicating a mid-cap profile suitable for investors seeking exposure to healthcare with moderate growth potential.
Market Position and Sector
LivaNova operates in the Medical – Devices industry within the Healthcare sector. Its diversified portfolio of devices supports critical care treatments, giving it resilience against market fluctuations driven by single product lines.
The company’s reach in cardiopulmonary and neuromodulation positions it among a specialized group of healthcare manufacturers serving both chronic and acute medical needs.
Governance and Leadership
Vladimir A. Makatsaria serves as the Chief Executive Officer, bringing experience and strategic direction to the company. Leadership stability in the medical device industry is essential for navigating regulatory requirements, clinical trial processes, and commercialization pathways.
With around 2,900 full-time employees, LivaNova has the human resources to maintain research, development, manufacturing, and global distribution channels efficiently.
Key Financial Data
- Share Price: USD 53.37
- Change: +1.22 (+2.34%)
- 52-Week Range: USD 32.48 – USD 58.91
- Market Capitalization: USD 2.91 billion
- Dividend: None
- Volume: 243,067 shares
- Average Volume: 662,609 shares
For investors, the 52-week range provides a perspective on volatility and price recovery potential. Market capitalization indicates the size and value of the company in the equity market. The no-dividend policy signals growth reinvestment. Volume metrics help gauge liquidity and trading interest.
FAQ
- Does LivaNova pay dividends? No. The last dividend was zero, reflecting a focus on reinvestment.
- Where is LivaNova traded? On the NASDAQ Global Select Market, under the ticker LIVN.
- What is the ISIN and CUSIP code? ISIN: GB00BYMT0J19, CUSIP: G5509L101.
- How many employees does LivaNova have? Approximately 2,900 full-time employees.
- Who is the CEO? Vladimir A. Makatsaria.
Conclusion
LivaNova PLC shows steady progress in market positioning within the medical device sector. Recent gains may attract investors seeking exposure to healthcare technologies. However, careful review of liquidity, volume patterns, and growth strategy is warranted before making decisions.
Disclaimer
This information is for informational purposes only and does not constitute financial advice. Investors should conduct independent research before making investment decisions.
Announcement
For full information about the company, see the link below.